Nifuratel

Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[4936-47-4]

Product Name Alternative

NF 113; SAP 113; Methylmercadone

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Apoptosis; Bacterial; Fungal; Interleukin Related; Parasite; STAT; TNF Receptor

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nifuratel.html

Purity

99.93

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1OC(CSC)CN1/N=C/C2=CC=C([N+]([O-])=O)O2

Molecular Formula

C10H11N3O5S

Molecular Weight

285.28

Precautions

H302, H315, H319, H335

References & Citations

[1]Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012 Feb 1;7 (1) :36-40.|[2]Nijevitch AA, et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy withnifuratel to furazolidone. Aliment Pharmacol Ther. 2005 Nov 1;22 (9) :881-7.|[3]Nijevitch AA, et al. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007 Apr;12 (2) :132-5.|[4]Xie T, et al. Nifuratel reduces Salmonella survival in macrophages by extracellular and intracellular antibacterial activity[J]. Microbiology Spectrum, 2023, 11 (5) : e05147-22.|[5]Zheng H, et al. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells[J]. Cancer management and research, 2017: 565-572.|[6]Lee J E, et al. Drug repositioning of anti-microbial agent nifuratel to treat mast cell-mediated allergic responses[J]. International Journal of Immunopathology and Pharmacology, 2023, 37: 03946320231202349.|[7]Mendling W, et al. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections[J]. Arzneimittelforschung, 2002, 52 (01) : 8-13.|[8]Tynan A P, et al. Nifuratel in urinary infections[J]. British Journal of Urology, 1969, 41 (3) : 271-279.